Vaccine rollout ‘relied on GP goodwill’: Study General practices involved in Australia’s COVID-19 vaccination program struggled to make ends meet, researchers say.
TGA provisionally approves first prevention therapy for COVID-19 The combination therapy, created by AstraZeneca, has been described as another ‘significant step forward’ in the pandemic.
TGA approval clarifies AstraZeneca booster use While vaccinators could already use AstraZeneca as a booster in certain circumstances, the TGA decision may make the option clearer to the public.
Do current COVID-19 vaccines and treatments neutralise Omicron? New research has looked into a number of medications currently approved for use in Australia, as well as the role of a booster shot against the highly-infectious variant.
COVID-19 chart updated with Omicron risk of death, benefits of boosters GPs can now access up-to-date data on the benefits of booster doses for patients who have received AstraZeneca as their primary course based on risks of Omicron transmission.
Top stories of 2021: Part four A combination of freedoms, lockdowns, surging cases, mask rules, a complicated vaccine rollout, and more has made it an eventful year for GPs.
COVID-19 Vaccine Claims Scheme now open GPs will play a leading role by providing a medical report for potential claimants under the scheme.
Guillain-Barré Syndrome deaths ‘likely linked’ to COVID vaccine An independent expert group has confirmed the two fatal cases are likely linked to AstraZeneca, but the complexity of the syndrome means uncertainties remain.
Vaccine myocarditis risk reaches 1 in 10,000 for adolescent boys But while the rate of Pfizer-related myocarditis continues to increase in males aged 12–17, research cited by the TGA indicates the risk is still dwarfed by the threat COVID-19 poses to this cohort.
How vaccine companies are responding to Omicron Scientists are scrambling to test and potentially update their vaccine candidates against the latest COVID variant of concern.